Skip to content

Study on the safety of modified MCT ketogenic diet and standard therapy combination therapy for breast cancer patients

Study on the safety of modified MCT ketogenic diet and standard therapy combination therapy for breast cancer patients - Study on MCT ketogenic diet for breast cancer patients

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000044125
Enrollment
50
Registered
2021-05-07
Start date
2021-05-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Sponsors

Toho University Omori Medical Center, Department of Nutrition Therapy Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Cases of standard treatment according to the breast cancer clinical practice guidelines published by the Japan Breast Cancer Society

Exclusion criteria

Exclusion criteria: 1. Weight loss of 5% or more has been observed in the last 3 months. 2. Highly advanced example (Exclusion example) When there is liver metastasis, deterioration of liver function, jaundice, and ascites. (Exclusion example) When there is lung metastasis and there are clinical symptoms such as pleural effusion and respiratory distress. However, bone metastases and brain metastases are not excluded. 3. If you have a history of ileus or peritoneal dissemination.

Design outcomes

Primary

MeasureTime frame
safety Presence or absence of diarrhea or allergic symptoms b. Dehydration, symptomatological hypoglycemia, excessive ketosis, gastrointestinal symptoms Nutritional status (body weight, body composition analysis using In Body (BIA), serum albumin, serum cholinesterase, serum transthyretin, CRP), QOL score (EORTCQLQ-CR38 Japanese version, POMS2 Japanese version)

Secondary

MeasureTime frame
Response rate, pathological control rate, surgical transition rate, transition of tumor markers (including serum anti-p53 antibody titer), PET scan in the clinical range, blood glucose and ketone body measurement using FreeStyle Libre outside the hospital for those who wish Give guidance. In addition, for possible cases, serum and urinary ketone bodies and urinary 8-OHdG will be measured.

Countries

Japan

Contacts

Public ContactNaohiro Washizawa

Toho University Omori Medical Center Nutrition Therapy Center

washi@med.toho-u.ac.jp0337624151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026